OCALIVA received FDA accelerated approval in 2016 for the treatment of PBC in adults with an inadequate response to or intolerance of ursodeoxycholic acid (UDCA). Since then, OCALIVA has played a ...

Intercept Pharmaceuticals has voluntarily pulled Ocaliva (obeticholic acid) from the US market following a request from the ...

Intercept Pharmaceuticals has voluntarily removed Ocaliva from the United States market for the treatment of primary biliary ...

Ocaliva won accelerated approval for primary biliary cholangitis in 2016, which the FDA refused to upgrade to full approval ...

Intercept Pharmaceuticals withdraws Ocaliva from the U.S. market following FDA concerns over safety and effectiveness for ...

A two-way relationship was observed between T1D and primary biliary cholangitis (PBC): genetically predicted T1D increased ...

– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in ...

Intercept Pharmaceuticals has pulled obeticholic acid (Ocaliva) from the U.S. market as a treatment for primary biliary ...

Seladelpar is an oral, selective peroxisome proliferator-activated receptor delta agonist. Treatment with seladelpar was associated with an improvement in cholestatis markers in patients with primary ...

This indication was approved under accelerated approval based on a reduction of alkaline phosphatase. The Food and Drug Administration (FDA) has granted accelerated approval to Iqirvo ® (elafibranor) ...

The Business Research Company's Primary Biliary Cholangitis Therapeutics Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 Get 30% Off All Global Market Reports With Code ...